Weekly Clinical Updates

Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA | U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States | Vaccination with BCG-Denmark did not result in a lower risk of Covid-19 among health care workers than placebo |NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial | Comparative effectiveness of the sars-CoV-2 vaccines during Delta dominance | Clinical Outcomes Following Treatment for COVID-19 | Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study | Association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market | Researchers disagree over how bad it is to be reinfected, and whether COVID-19 can cause lasting changes to the immune system | Virtual Care and Emergency Department Use During the COVID-19 Pandemic Among Patients of Family Physicians in Ontario, Canada | Assessment of Gender-Specific COVID-19 Case Fatality Risk per Malignant Neoplasm Type | Timing of intubation and ICU mortality in COVID-19 patients

SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis | Completeness and Spin of medRxiv Preprint and Associated Published Abstracts of COVID-19 Randomized Clinical Trials | Risk of new-onset Long Covid following reinfection with SARS-CoV-2: community-based cohort study | Low vitamin D levels are associated with Long COVID syndrome in COVID-19 survivors | Effectiveness of Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine | Molnupiravir and risk of post-acute sequelae of COVID-19 | Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19” | Lessons Learned From a COVID-19 Dog Screening Pilot in California K-12 Schools

Update on Vaccine-Derived Poliovirus Outbreaks | Sleep Disturbance Severity and Correlates | Two individuals with potential monkeypox virus reinfection | Risk of autoimmune diseases in patients | FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines | SARS-CoV-2 neutralizing antibodies | Durability of Bivalent Boosters against Omicron Subvariants | Nirmatrelvir and risk of hospital admission or death in adults | Evolving Real-World Effectiveness of Monoclonal Antibodies | Effect of Angiotensin-Converting Enzyme Inhibitor | Efficacy and Safety of Anakinra Plus Standard | Higher dose corticosteroids in patients admitted to hospital | Risk of Death in Patients Hospitalized for COVID-19 | Recent French mpox cluster includes fully vaccinated patients | Epidemiologic and Clinical Features of Mpox-Associated Deaths | SARS-CoV-2 During Omicron Variant Predominance | Severe Maternal Morbidity and Mortality of Pregnant Patients | Sickness presenteeism in healthcare workers | Ventilation Improvements Among K–12 Public School Districts | Risk factors and vectors for SARS-CoV-2 household transmission | Definition of Post–COVID-19 Condition

Prevalence and Characteristics Associated With Post–COVID-19 Condition | The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection | Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome | Vaccine effectiveness against hospitalization among adolescent cases | Effectiveness of BNT162b2 after extending the primary series dosing interval in children | Within-host genetic diversity of SARS-CoV-2 | Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants | Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection | COVID-19 convalescent plasma utilization in the United States | FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19 | Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients | Anti-C5a antibody (vilobelimab) therapy for critically ill patients | Triple combination therapy with two antivirals | Adeno-associated virus type 2 in US children | Genomic investigations of unexplained acute hepatitis in children | Surveillance of SARS-CoV-2 at the Huanan Seafood Market

Severe Infection and Risk of Cardiovascular Disease | Risk Factors Associated With Post−COVID-19 Condition | Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization | Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition | Antibiotics don't reduce risk of death from viral respiratory infections | ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study | Mechanically Ventilated Patients With Coronavirus Disease 2019 Had a Higher Chance of In-Hospital Death If Treated With High-Flow Nasal Cannula Oxygen Before Intubation

Prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction | A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story | Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households | Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system | Projected COVID-19 Mortality Reduction From Paxlovid Rollout | SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity | Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection: an individual participant data meta-analysis | Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers